204 F.Supp.3d 665
D. Del.2016Background
- Sanofi (Multaq® NDA for dronedarone 400 mg) sued generic makers (including Watson and Sandoz) after Paragraph IV ANDA filings alleging infringement of patents ‘800 (composition) and ‘167 (method-of-treatment). Trial focused on infringement and validity of the ‘167 patent and a claim-construction issue arising from the ‘800 prosecution history.
- The ‘167 patent claims methods of reducing cardiovascular hospitalization (or AF hospitalization) by administering dronedarone twice daily with morning and evening meals to AF patients who do not have severe heart failure and who have at least one of six listed cardiovascular risk factors; several dependent claims add diuretic co‑treatment and a ≥12‑month treatment limitation.
- Defendants’ proposed labels copy Sanofi’s Multaq® label. The ATHENA clinical trial is prominently described in the labels and is the only trial in the labels reporting the reduction in cardiovascular/AF hospitalizations; ATHENA enrolled the claimed risk‑factor population.
- At trial the court adopted Sanofi’s POSA definition (cardiology/electrophysiology clinician with ≥2 years post‑fellowship experience) and used 2008 as the reference timeframe for obviousness and other prior‑art questions.
- The court found (1) Defendants’ proposed labels induce infringement of most asserted claims of the ‘167 patent (but not claim 5), (2) no contributory infringement because substantial non‑infringing uses exist, (3) the asserted ‘167 claims are not invalid for obviousness or public use, and (4) the polysorbate disclaimer in the parent ‘493 patent does not carry over to the ‘800 patent.
Issues
| Issue | Plaintiff's Argument (Sanofi) | Defendant's Argument (Watson/Sandoz) | Held |
|---|---|---|---|
| Inducement of ‘167 independent claims (risk‑factor limitation) | Labels direct physicians to Indications → Clinical Studies (ATHENA). ATHENA population matches claimed risk factors; thus label encourages prescribing to claimed patients and Sanofi showed actual prescribing statistics. | Labels do not explicitly limit use to risk‑factor patients; Clinical Studies covers multiple trials (E/A trials show benefit in non‑risk patients); many prescriptions are for non‑risk patients, so no specific intent to induce. | Labels induce infringement of claims 1, 8 and dependent claims (except where noted). Court: labels will "inevitably" lead some physicians to the claimed use; defendants knew of the patent and knew use was infringing. |
| Inducement / dependent claims 4, 5 (diuretics) and 10 (≥12 months) | ATHENA description shows many patients took diuretics and results were consistent across subgroups; ATHENA median treatment ≈22 months—labels encourage co‑treatment and long‑term use. | Labels do not expressly direct concomitant diuretics nor specify 12‑month duration; no explicit instruction to induce these narrower claims. | Inducement found for claim 4 (diuretic‑based treatment) and claim 10 (≥12 months). No inducement found for claim 5 (non‑potassium‑sparing diuretics) because warnings do not encourage that use. |
| Contributory infringement under §271(c) | Defendants’ product is labeled in a way that targets the patented use; off‑label uses are not a defense because promotion for non‑patented uses is limited. | There are substantial non‑infringing uses (~15–23% of prescriptions for non‑risk patients); some uses are on‑label per E/A language; thus product is suitable for substantial non‑infringing uses. | No contributory infringement. Court: substantial non‑infringing uses exist, so §271(c) liability does not attach. |
| Obviousness of the ‘167 claims | The prior art (Hohnloser 2008, ClinicalTrials.gov ATHENA protocol, and 2006 EMEA report re: BID dosing) would have given a POSA a reasonable expectation that dronedarone would reduce cardiovascular/AF hospitalizations in the ATHENA population. | Hohnloser 2008 and E/A post‑hoc analyses were hypotheses/not definitive; post‑hoc results are unreliable, ANDROMEDA raised serious safety concerns, and prior AADs with similar properties had not reduced hospitalizations—no reasonable expectation of success. | Claims are not obvious. Court: a POSA in 2008 would be skeptical; Hohnloser’s language was a hypothesis to be tested and post‑hoc evidence + negative ANDROMEDA data undercut a reasonable expectation of success. Secondary considerations (commercial success, praise, long‑felt need) support nonobviousness. |
| Public‑use bar (§102(b)) re: ATHENA trial before critical date | ATHENA patient treatments met claim elements and the trial was not confidential for patients; invention was "ready for patenting" based on prior studies, so public use invalidates the patent. | ATHENA was experimental clinical testing (quintessential experimental use); investigators bound by confidentiality; inventors did not know results before April 16, 2008—patent not ready for patenting. | No public‑use bar. Court: ATHENA was experimental, inventors lacked reduction‑to‑practice before the critical date, and confidentiality/absence of commercial exploitation negated §102(b). |
| Claim construction / prosecution disclaimer (’800 patent: "nonionic hydrophilic surfactant" vs polysorbates) | Disavowal in parent ‘493 prosecution excluded polysorbates; that disclaimer should bind the child ‘800 patent. | ‘800 claims omit the explicit anti‑polysorbate limitation that produced the disclaimer in the parent; the applicant did not advance lack of polysorbates during ‘800 prosecution and the examiner treated polysorbates as within scope. | Parent’s polysorbate disclaimer does not carry over. Court: disclaimer arose from explicit claim language in the parent that is absent from the ‘800 claims; prosecution history of the ‘800 shows examiner and applicant treated polysorbates as within scope. |
Key Cases Cited
- Markman v. Westview Instruments, Inc., 52 F.3d 967 (Fed. Cir. 1995) (establishes claim‑construction/Markman framework)
- KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (U.S. 2007) (obviousness analysis and obvious‑to‑try guidance)
- AstraZeneca LP v. Apotex, Inc., 633 F.3d 1042 (Fed. Cir. 2010) (Hatch‑Waxman label‑inducement: label need not literally track claims to induce)
- Takeda Pharm. USA, Inc. v. West‑Ward Pharm. Corp., 785 F.3d 625 (Fed. Cir. 2015) (inducement requires clear encouragement, not mere speculation)
- Global‑Tech Appliances, Inc. v. SEB S.A., 563 U.S. 754 (U.S. 2011) (knowledge/willful blindness standard for induced infringement)
- Fujitsu Ltd. v. Netgear Inc., 620 F.3d 1321 (Fed. Cir. 2010) (elements of contributory infringement under §271(c))
- In re Cyclobenzaprine Hydrochloride Extended‑Release Capsule Patent Litig., 676 F.3d 1063 (Fed. Cir. 2012) (limitations on obvious‑to‑try, and need for finite predictable options)
- Cammi! USA, LLC v. Cisco Sys., Inc., 135 S. Ct. 1920 (U.S. 2015) (knowledge requirement for inducement reaffirmed)